The P-III (VLA2001-301) Cov-Compare study evaluates VLA2001 vs ChAdOx1-S in 4012 patients with COVID-19. Following the administration of the booster dose, patients will be followed for ~6mos.
The results showed persistent immunogenicity at ~2mos.; neutralizing Ab titers were non-inferior to ChAdOx1-S & seroconversion rates remained constant at Day 71 (≥92%). The analysis of T-cell responses on Day 208 revealed that VLA2001 had induced broad Ag-specific IFN-gamma-producing T-cells reactive against S, N & M-proteins
The heterologous booster results for VLA2001 boosted immunity to higher neutralizing Abs titers in patients primed with ChAdOx1-S. The tolerability profile of a booster dose was similar to the favorable profile after 1st & the 2nd vaccination
Ref: Globe Newswire | Image: Valneva
